On Wednesday, Pfizer announced the Canadian launch of Abrysvo, its respiratory syncytial virus (RSV) vaccine for infants and people over 60 years of age.

The vaccine becomes the only RSV vaccine available in Canada for the active immunization of pregnant women between the 32nd and 36th weeks of pregnancy, to prevent lower respiratory tract disease in infants from birth to six months of age.

Last December, Health Canada - the Canadian health authority - approved the vaccine for the prevention of both severe and mild lower respiratory tract illnesses caused by RSV.

Copyright (c) 2024 CercleFinance.com. All rights reserved.